PT - JOURNAL ARTICLE AU - Raiser, Fritz AU - Davis, Matthew AU - Adelglass, Jeffrey AU - Cai, Miranda R. AU - Chau, Gordon AU - Cloney-Clark, Shane AU - Eickhoff, Mark AU - Kalkeri, Raj AU - McKnight, Irene AU - Plested, Joyce AU - Zhu, Mingzhu AU - Dunkle, Lisa AU - , TI - Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adults AID - 10.1101/2023.03.16.23287030 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.16.23287030 4099 - http://medrxiv.org/content/early/2023/03/20/2023.03.16.23287030.short 4100 - http://medrxiv.org/content/early/2023/03/20/2023.03.16.23287030.full AB - Background To combat the SARS-CoV-2 pandemic, multiple vaccines using different manufacturing platforms have been developed, including NVX-CoV2373 (an adjuvanted recombinant protein vaccine). As SARS-CoV-2 variants have emerged, some of which evade vaccine-induced immunity, introduction of vaccine booster doses has become critical. Employing different vaccine types for primary series vaccination and boosting could expand vaccine coverage and access. This study assessed whether NVX-CoV2373 would induce similar responses when used as a heterologous or homologous booster.Methods The 2019nCoV-307 study was a phase 3, randomized, observer-blinded trial evaluating immunogenicity and safety of NVX-CoV2373 in previously vaccinated adults aged 18-49 years in the United States (NCT05463068). Participants were randomized 1:1:1 to receive one intramuscular injection of NVX-CoV2373 from one of three different manufacturing lots. Immunogenicity was assessed by immunoglobulin G (IgG) and neutralizing antibodies (NAb). These responses were compared for the three lots, and for participants with primary series with or without a prior booster dose of the mRNA-1273, BNT162b2, Ad26.COV2.S, or NVX-CoV2373 COVID-19 vaccines.Results A total of 911 participants were randomized between July 11 and 13, 2022, with 905 being assessed for safety and 848 for immunogenicity. Immunogenicity of NVX-CoV2373 met prespecified equivalence criteria between lots, and the booster dose was well-tolerated. NVX-CoV2373 induced robust IgG and NAb responses when used as a first or later booster dose, regardless of primary series vaccine type. Seroconversion rates were also similar across previous vaccine types. Induced antibodies were strongly reactive, even to the immune-evasive Omicron BA.1 and BA.5 variants.Conclusions NVX-CoV2373 showed consistent immunogenicity between lots, with no new safety signals identified. Use of NVX-CoV2373 as a homologous or heterologous booster dose (first or later) is supported.Competing Interest StatementMRC, GC, SCC, ME, RK, IM, JP, MZ, and LMD are all employees and stockholders of Novavax, Inc. FR, MD, and JA are Investigators of the study and do not have any conflicts to report. Clinical TrialNCT05463068Funding StatementThis work was supported by Novavax, Inc. with support from the US Biomedical Advanced Research and Development Authority (Contract W15QKN-16-9-1002, Project Number MCDC2011-001.).The sponsor had primary responsibility for study design, study vaccines, protocol development, study monitoring, data management, and statistical analyses. All authors reviewed and approved the manuscript before submission. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed, approved and overseen by the Advarra Institutional Review Board, Columbia, MD.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesStudy information is available at https://clinicaltrials.gov/ct2/show/NCT05463068 and requests will be considered.